177 related articles for article (PubMed ID: 37224516)
1. Precision diagnosis and staging of TDP-43 proteinopathies: harnessing the power of artificial intelligence.
Hickman RA; Scholz SW
Brain; 2023 Jul; 146(7):2666-2668. PubMed ID: 37224516
[TBL] [Abstract][Full Text] [Related]
2. TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes.
Tan RH; Kril JJ; Fatima M; McGeachie A; McCann H; Shepherd C; Forrest SL; Affleck A; Kwok JB; Hodges JR; Kiernan MC; Halliday GM
Brain; 2015 Oct; 138(Pt 10):3110-22. PubMed ID: 26231953
[TBL] [Abstract][Full Text] [Related]
3. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated.
Robinson JL; Lee EB; Xie SX; Rennert L; Suh E; Bredenberg C; Caswell C; Van Deerlin VM; Yan N; Yousef A; Hurtig HI; Siderowf A; Grossman M; McMillan CT; Miller B; Duda JE; Irwin DJ; Wolk D; Elman L; McCluskey L; Chen-Plotkin A; Weintraub D; Arnold SE; Brettschneider J; Lee VM; Trojanowski JQ
Brain; 2018 Jul; 141(7):2181-2193. PubMed ID: 29878075
[TBL] [Abstract][Full Text] [Related]
4. Data-driven neuropathological staging and subtyping of TDP-43 proteinopathies.
Young AL; Vogel JW; Robinson JL; McMillan CT; Ossenkoppele R; Wolk DA; Irwin DJ; Elman L; Grossman M; Lee VMY; Lee EB; Hansson O
Brain; 2023 Jul; 146(7):2975-2988. PubMed ID: 37150879
[TBL] [Abstract][Full Text] [Related]
5. Disease animal models of TDP-43 proteinopathy and their pre-clinical applications.
Liu YC; Chiang PM; Tsai KJ
Int J Mol Sci; 2013 Oct; 14(10):20079-111. PubMed ID: 24113586
[TBL] [Abstract][Full Text] [Related]
6. Perfusion alterations converge with patterns of pathological spread in transactive response DNA-binding protein 43 proteinopathies.
Ferraro PM; Jester C; Olm CA; Placek K; Agosta F; Elman L; McCluskey L; Irwin DJ; Detre JA; Filippi M; Grossman M; McMillan CT
Neurobiol Aging; 2018 Aug; 68():85-92. PubMed ID: 29751289
[TBL] [Abstract][Full Text] [Related]
7. Molecular dissection of TDP-43 proteinopathies.
Hasegawa M; Nonaka T; Tsuji H; Tamaoka A; Yamashita M; Kametani F; Yoshida M; Arai T; Akiyama H
J Mol Neurosci; 2011 Nov; 45(3):480-5. PubMed ID: 21678031
[TBL] [Abstract][Full Text] [Related]
8. [FTLD/ALS as TDP-43 proteinopathies].
Ishihara T; Ariizumi Y; Shiga A; Yokoseki A; Sato T; Toyoshima Y; Kakita A; Takahashi H; Nishizawa M; Onodera O
Rinsho Shinkeigaku; 2010 Nov; 50(11):1022-4. PubMed ID: 21921552
[TBL] [Abstract][Full Text] [Related]
9. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis.
Suk TR; Rousseaux MWC
Mol Neurodegener; 2020 Aug; 15(1):45. PubMed ID: 32799899
[TBL] [Abstract][Full Text] [Related]
10. Perry Syndrome: A Distinctive Type of TDP-43 Proteinopathy.
Mishima T; Koga S; Lin WL; Kasanuki K; Castanedes-Casey M; Wszolek ZK; Oh SJ; Tsuboi Y; Dickson DW
J Neuropathol Exp Neurol; 2017 Aug; 76(8):676-682. PubMed ID: 28789478
[TBL] [Abstract][Full Text] [Related]
11. Amyotrophic Lateral Sclerosis with Pallidonigroluysian Degeneration: A Clinicopathological Study.
Ito J; Shimizu H; Ohta K; Idezuka J; Tanaka H; Kondo H; Nakajima T; Takahashi H; Akazawa K; Onodera O; Kakita A
Ann Neurol; 2020 Feb; 87(2):302-312. PubMed ID: 31773773
[TBL] [Abstract][Full Text] [Related]
12. The Role of TDP-43 in Neurodegenerative Disease.
Liao YZ; Ma J; Dou JZ
Mol Neurobiol; 2022 Jul; 59(7):4223-4241. PubMed ID: 35499795
[TBL] [Abstract][Full Text] [Related]
13. Quantitative patterns of motor cortex proteinopathy across ALS genotypes.
Nolan M; Scott C; Gamarallage MP; Lunn D; Carpenter K; McDonough E; Meyer D; Kaanumalle S; Santamaria-Pang A; Turner MR; Talbot K; Ansorge O
Acta Neuropathol Commun; 2020 Jul; 8(1):98. PubMed ID: 32616036
[TBL] [Abstract][Full Text] [Related]
14. Retrospective neuropathological diagnosis of TDP-43 proteinopathies: Factors affecting immunoreactivity of phosphorylated TDP-43 in fixed post-mortem brain tissue.
Robinson AC; Davidson YS; Minshull J; Lally I; Walker L; Mann DMA; Roncaroli F
Neuropathology; 2024 Apr; 44(2):173-179. PubMed ID: 37528690
[No Abstract] [Full Text] [Related]
15. Slow motor neurons resist pathological TDP-43 and mediate motor recovery in the rNLS8 model of amyotrophic lateral sclerosis.
Hur SK; Hunter M; Dominique MA; Farag M; Cotton-Samuel D; Khan T; Trojanowski JQ; Spiller KJ; Lee VM
Acta Neuropathol Commun; 2022 May; 10(1):75. PubMed ID: 35568882
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of TDP-43 Proteinopathy Onset and Propagation.
Chen HJ; Mitchell JC
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199367
[TBL] [Abstract][Full Text] [Related]
17. TDP-43 protein interactome informs about perturbed canonical pathways and may help develop personalized medicine approaches for patients with TDP-43 pathology.
Helmold BR; Pauss KE; Ozdinler PH
Drug Discov Today; 2023 Nov; 28(11):103769. PubMed ID: 37714405
[TBL] [Abstract][Full Text] [Related]
18. Abnormal regenerative responses and impaired axonal outgrowth after nerve crush in TDP-43 transgenic mouse models of amyotrophic lateral sclerosis.
Swarup V; Audet JN; Phaneuf D; Kriz J; Julien JP
J Neurosci; 2012 Dec; 32(50):18186-95. PubMed ID: 23238732
[TBL] [Abstract][Full Text] [Related]
19. Seeding the aggregation of TDP-43 requires post-fibrillization proteolytic cleavage.
Kumar ST; Nazarov S; Porta S; Maharjan N; Cendrowska U; Kabani M; Finamore F; Xu Y; Lee VM; Lashuel HA
Nat Neurosci; 2023 Jun; 26(6):983-996. PubMed ID: 37248338
[TBL] [Abstract][Full Text] [Related]
20. Glial TDP-43 and TDP-43 induced glial pathology, focus on neurodegenerative proteinopathy syndromes.
Prater KE; Latimer CS; Jayadev S
Glia; 2022 Feb; 70(2):239-255. PubMed ID: 34558120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
